Form 4: CFO Sims' RSU Vesting Boosts PLUS THERAPEUTICS Stake

PLUS THERAPEUTICS CFO Andrew Sims reported the vesting of 38,323 Restricted Stock Units, increasing his direct beneficial ownership of common stock.

Summary

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), reported a transaction involving the company's securities.
• On October 1, 2025, 38,323 Restricted Stock Units (RSUs) vested, converting into an equal number of common stock shares.
• Each RSU represents a contingent right to receive one share of the issuer's Common Stock.
• The vesting occurred at a price of $0 per share, as it represents the conversion of previously granted compensation.
• Following this transaction, Mr. Sims directly beneficially owns 48,138 shares of Common Stock.
• He also continues to beneficially own 421,555 Restricted Stock Units.
• This vesting is part of a schedule that occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects a routine increase in insider ownership, aligning executive interests with shareholders. It's not highly impactful but generally viewed favorably.

Positives

• The vesting of Restricted Stock Units increases the direct beneficial ownership of common stock by a key executive, Andrew Sims, aligning his interests further with shareholders.
• The transaction is a routine compensation event, indicating stability in executive compensation plans.

Future Outlook

The vesting of Restricted Stock Units for Andrew Sims is scheduled to occur in twelve substantially equal quarterly installments beginning on October 1, 2025, indicating a pre-determined long-term compensation structure.

Industry Context

This filing represents a routine insider compensation event, which is common across publicly traded companies as a mechanism to align executive incentives with long-term shareholder value. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through greater direct stock ownership.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Future quarterly installments of RSU vesting for Andrew Sims as per the established schedule.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled vesting of Restricted Stock Units for a key executive. While it increases insider ownership, it does not represent a new investment decision by the executive or a change in the company's fundamental outlook. Therefore, it does not provide new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate as it's a non-event for the investment thesis.

Keywords

PLUS THERAPEUTICS, PSTV, Andrew Sims, CFO, Restricted Stock Units, RSU vesting, insider transaction, beneficial ownership, SEC Form 4